StockNews.AI
FENC
StockNews.AI
166 days

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

1. Fennec Pharmaceuticals will release financial results on March 10, 2025. 2. A conference call will discuss 2024 performance and business results. 3. PEDMARK has FDA and European approval, enhancing competitive position. 4. FENC holds Orphan Drug Exclusivity and market protection in key regions.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive financial updates can lead to increased investor confidence, similar to past earnings reports boosting stock prices.

How important is it?

The financial results announcement is significant, likely influencing investor sentiment and trading volume.

Why Short Term?

Immediate interest in upcoming results can drive price fluctuations leading up to the announcement.

Related Companies

FENCFRX
March 06, 2025 16:22 ET  | Source: Fennec Pharmaceuticals Inc. RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days. About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com. For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate and Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

Related News